Phamacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer by Miolo, Gianmaria et al.
Oncotarget39809www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 26
Pharmacometabolomics study identifies circulating spermidine 
and tryptophan as potential biomarkers associated with the 
complete pathological response to trastuzumab-paclitaxel 
neoadjuvant therapy in HER-2 positive breast cancer
Gianmaria Miolo1, Elena Muraro2, Donatella Caruso3, Diana Crivellari1, Anthony Ash4, 
Simona Scalone1, Davide Lombardi1, Flavio Rizzolio2, Antonio Giordano5, Giuseppe 
Corona2
1Department of Medical Oncology, IRCCS-National Cancer Institute, Aviano, Italy
2Department of Translational Research, IRCCS-National Cancer Institute, Aviano, Italy
3Department of Pharmacological and Bimolecular Science, University of Milan, Milan, Italy
4Department of Biological Chemistry, Norwich Research Park, Norwich, United Kingdom
5Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, 
Temple University, Philadelphia, PA, USA
Correspondence to: Giuseppe Corona, email: giuseppe.corona@cro.it
Keywords: pharmacometabolomics, pharmacometabonomics, metabolomics, breast, cancer
Received: October 30, 2015    Accepted: April 28, 2016    Published: May 19, 2016
ABSTRACT
Defining biomarkers that predict therapeutic effects and adverse events is a 
crucial mandate to guide patient selection for personalized cancer treatments. In the 
present study, we applied a pharmacometabolomics approach to identify biomarkers 
potentially associated with pathological complete response to trastuzumab-paclitaxel 
neoadjuvant therapy in HER-2 positive breast cancer patients. Based on histological 
response the 34 patients enrolled in the study were subdivided into two groups: good 
responders (n = 15) and poor responders (n = 19). The pre-treatment serum targeted 
metabolomics profile of all patients were analyzed by liquid chromatography tandem 
mass spectrometry and the differences in the metabolomics profile between the two 
groups was investigated by multivariate partial least squares discrimination analysis. 
The most relevant metabolites that differentiate the two groups of patients were 
spermidine and tryptophan. The Good responders showed higher levels of spermidine 
and lower amounts of tryptophan compared with the poor responders (p < 0.001,  
q < 0.05). The serum level of these two metabolites identified patients who achieved a 
pathological complete response with a sensitivity of 90% [0.79–1.00] and a specificity 
of 0.87% [0.67–1.00]. These preliminary results support the role played by the 
individual patients’ metabolism in determining the response to cancer treatments 
and may be a useful tool to select patients that are more likely to benefit from the 
trastuzumab-paclitaxel treatment.
INTRODUCTION
The introduction of trastuzumab revolutionized 
the treatment of HER-2-positive breast cancer (BC) and 
now represents the gold standard drug used alongside 
other pharmacological regimens both in adjuvant and 
neoadjuvant settings [1–4]. The latter approach may be 
able to reduce the tumour mass of locally advanced BC, 
decrease the subclinical micro-metastatic disease and 
improve the rates of breast-conserving surgeries [1, 5]. 
In this setting, the induction of a pathological complete 
response (pCR), i.e. the absence of cancer cells in breast 
tissue after therapy, is associated with improved disease 
free survival (DFS), overall survival (OS) and reduced 
relapse rates [6, 7]. Even if the addition of trastuzumab 
strongly increased the pCR rates in HER-2 positive BC 
patients [8] there is still a significant subgroup of patients 
that does not benefit from this treatment [9]. For this 
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reason, the identification of specific biomarkers that are 
able to predict an unfavourable response to trastuzumab-
based neoadjuvant treatment could be clinically useful in 
order to select more effective treatments. 
The survey for biomarkers, managed both through 
retrospective clinical analysis and gene expression studies 
[10] proved to be very challenging, showing that also the 
level of HER-2 expression, the most obvious candidate 
biomarker for HER-2 targeting therapy, resulted to be 
surprisingly ambiguous [11–13]. The multifaceted mode of 
action of trastuzumab may be responsible for the difficulty 
in identifying, predictive biomarkers since as monoclonal 
antibody trastuzumab acts also through immune-mediated 
mechanisms that involve host immune cells [14]. The 
required contribution of host effectors suggests a direct 
involvement of individuals’ endogenous biochemical 
factors, which could thus represent an innovative and 
complementary front for predictive biomarkers research. 
Moreover, other recently proposed surrogate markers of 
response to neoadjuvant treatment are based on patients’ 
characteristics such as the body mass index (BMI). Indeed, 
a higher BMI was found associated with lower rate of pCR 
and a detrimental impact on survival [15]. This contributes 
to retain that the host response to the tumour is perhaps 
equally important to determining the pharmacological 
effect, which can be highlighted by an individual’s specific 
biochemical signature. 
Pharmacometabolomics is an innovative “omic” 
methodology that is able to access patients’ biochemical 
status and is therefore useful to understand the host’s 
response to drug treatments. This new approach is based 
on the identification of individuals’ metabolomic profiles, 
which represent a large repertoire of metabolites that may 
reflect the complex interactions among gene expression, 
protein expression, physio-pathological conditions, age, 
gut microbiome, and the environment better than other 
“omic” profiles. Consequently, the metabolomics profile 
is more closely associated to a patient’s pharmacological 
phenotype and could be more informative than genomic 
and proteomic data clarifying better the mechanisms of 
inter-patient variability to drug therapy [16–19]. The 
potential for pharmacometabolomics has already been 
demonstrated for different classes of drugs in preclinical 
investigations, as well as in clinical pharmacological 
settings [20–25]. A few investigations have been applied 
to the pharmacological treatment of BCs. In particular, two 
previous investigations analysed the predictive value of 
basal serum metabolites on the outcome of BC patients in 
the metastatic and neoadjuvant settings [26, 27] but their 
results were contradictory. One of these studies consisted 
of a pilot multicentric investigation that attempted to 
correlate the serum metabolomics profile with patient 
outcome and treatments toxicity [26]. However, this study 
failed to identify any correlations between the patients’ 
metabolomics profile and the therapies effect. More 
recently, a metabolomics investigation found that pCR 
correlated with changes in serum level of methionine, 
glutamine and linoleic acid [27]. However, the histological 
heterogeneity of the tumours and the different treatments 
administered limited the data interpretation for both these 
studies.
The present study was designed to explore the 
potential use of a pharmacometabolomics approach 
as a means to identify pre-treatment serum metabolite 
biomarkers associated with the pCR in a homogeneous 
monocenter cohort of HER-2 positive BC patients after 
neoadjuvant trastuzumab-paclitaxel treatment. We found 
that patients with lower serum concentrations of tryptophan 
and higher concentrations of spermidine responded more 
successfully to the treatment. This underlines the role that 
the  individual’s metabolic trait may have on determining 
the pharmacological outcome of cancer therapy.
RESULTS
Patient characteristics
The demographic and pathological characteristics 
of the patients investigated are reported in Table 1. 
Patients were divided into two groups according to 
their histological response to the trastuzumab-paclitaxel 
neoadjuvant treatment. The good responders (GR) 
(n = 15), who achieved pCR and the poor responders 
(PR) (n = 19), who achieved only a partial pathological 
response where residual disease was still revealed after 
the neoadjuvant treatment. The two groups did not differ 
significantly by age, BMI, tumour stage, grade and 
hormonal receptor expression. 
In both groups approximately half of the patients 
had hormone receptor positive tumours. Although not 
statistically significant at diagnosis, the GR group was 
characterized by a higher frequency of stage III tumours, 
which is generally indicative of a more aggressive 
phenotype with a relatively poor prognosis.
Metabolomics data analysis and biomarker 
identification
The pre-treatment serum targeted metabolomics 
profile data, determined by a validated LC-MS/MS, 
were analysed using supervisor partial least squares 
discrimination analysis (PLS-DA). This analysis was 
carried out to investigate if differences in the quantitative 
metabolomics profiles of the patients were able to 
distinguish the GR from the PR group. The results of this 
multi-parametric approach are summarized in the PLS-DA 
graph (Figure 1), where each point corresponds to the 
metabolite profile of each patient. From the quantitative 
metabolomics data, the GR group had a spatial distribution 
that was significantly different from that of PR group. 
The PSA-DA model was further refined to eliminate 
potential noise by focusing on the metabolites that showed 
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a significant difference among the two groups of patients. 
The internal cross validation of the refined PLS-DA 
model used in this study demonstrated good modelling 
and predictive capabilities (85% accuracy, good R2 (0.73) 
and Q2 (0.57). The values and permutation testing did not 
reveal any significant (p < 0.003) potential for over-fitting 
the model. 
In order to select the metabolites that showed 
a significant difference between the GR and PR 
metabolomic profiles a variable influence on the projection 
(VIP) parameter was used. The most relevant metabolites 
(VIP > 1) were: spermidine (Spd), tryptophan (Trp), 
propylcarnitine (C3) and the two phosphatidylcholine 
diacyl phospholipids (PC aa) PC aa C26:0 and PC aa 
C30:2 (Figure 2). The relative concentration distributions 
of such metabolites between the two groups of patients 
can be visualized in a heatmap (Figure 3). Among the five 
relevant metabolites (Spd; Trp; C3; PCaa C26:0 and PC aa 
C30:2), the difference in Spd concentration levels resulted 
the most clearly differentiated between the two groups. 
Furthermore, when an alternative statistical analysis was 
performed such as the Significance Analysis of Microarray 
(SAM) to account for potential False Discovery Rates 
(FDR), only Spd and Trp showed significant differences 
between the two groups of patients (Figure 4). The 
mean ± SD serum concentration of bioactive amine Spd 
in the GR group was significantly higher, 0.15 ± 0.06 mM 
vs 0.09 ± 0.032 mM (p < 0.001, q < 0.05), relative to the 
PR group. Whilst, the level of Trp was significantly lower 
in the GR group 61.19 ± 8.46 mM vs 73.82 ± 9.23 mM 
(p = 0.001, q < 0.05) relative to the PR group. 
Consequently, the anabolic and catabolic routes 
involved in the metabolism of Spd and Trp between the 
two groups of patients was further investigated. This 
analysis was carried out using the available quantitative 
metabolomics profile data, to explore any other associated 
metabolic alterations that could be potentially useful in 
the development of a predictive model for pCR after 
neoadjuvant trastuzumab-paclitaxel treatment.
Spermidine and tryptophan metabolic pathways
The Spd is a metabolite derived from the catabolic 
process of ornitine (Orn) to putrescine (Put) that requires 
methionine (Met) activation for its synthesis (Figure 5).
Table 1: Patients’ characteristics
Parameters GR PR p
Patients
 34 15 19
Age (years) NS#
 Median (range) 42 (28–58) 49 (23–70)
BMI (Kg/m2) NS#
 Mean ± SD 24.1 ± 4.9 25.8 ± 5.6
Stage NS#
 IIA 2 1
 IIB 8 16
 IIIA 5 2
Grade NS§
 G2 2 3
 G3 9 15
 Gx 4 1
ER/PgR NS§
 neg/neg 7 8
 pos/neg 4 3
 pos/pos 4 7
 neg/pos 0 1
# unpaired t-Test, § Chi-Square test. BMI Body mass index, ER:Estrogen receptors, PgR:
progesterone receptors.
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The quantitative data from the metabolomics profile 
indicated that between the GR and PR groups there were 
no significant differences in the serum levels of the Orn 
and Met precursors: 81 ± 16 mM vs 87 ± 22 mM for Orn 
and 18.87 ± 4.08 mM vs 21 ± 5 mM for Met, respectively. 
In addition, the serum level of Put showed no significant 
differences between the two groups of patients: GR 0.14 ± 
0.05 mM vs PR 0.13 ± 0.05 mM. Spermine, which is also 
involved in the pathway of bio-amine synthesis, was lower 
than the limit of detection for all patients investigated. The 
GR group characterized by a higher concentration of Spd 
as compared with the PR group, showed a significantly 
lower Orn/Spd ratio: 610 ± 205 vs 1107 ± 534 (p < 0.05) 
and a significantly lower Put/Spd ratio 1.0 ± 0.4 vs 1.6 ± 0.8 
(p < 0.05).
The Trp represents an essential amino acid that 
provides a building block to a vast array of proteins. It 
also acts as biochemical precursor for the synthesis of 
niacin cofactor, through pathways of kynurenine (Kyn) 
and for the synthesis of melatonin from serotonin (Set) via 
the methoxyindoles pathway (Figure 6). Within the Kyn 
pathway, the low serum level of Trp observed in the GR 
group was associated with a significantly (p < 0.05) lower 
level of the intermediate Kyn, 2.2 ± 0.4 vs 2.8 ± 0.7 mM, 
compared to the PR group. However, the ratio between 
Trp and Kyn showed no significant differences between 
two groups (27 ± 4 vs 28 ± 7). In addition, the mean serum 
concentrations of Set (via the methoxyindoles pathway) 
also showed no significant differences between the two 
groups, GR 0.60 ± 0.16 mM vs PR 0.55 ± 0.27 mM while 
the mean value of the Trp/Set ratio was significantly 
lower in the GR group compared with the PR group: 
108 ± 29 vs 159 ± 70, (p < 0.05) (Figure 6).
Receiver operating characteristic curve 
To demonstrate the diagnostic value of the two 
most relevant serum metabolites, a receiver operating 
characteristic (ROC) curve was applied to the data. 
This helped to evaluate the predictive power of the two 
metabolites in identifying patients that would best benefit 
from the neoadjuvant treatment. The ROC curves were 
produced using the serum concentration of Spd and Trp 
both independently and combined. The ROC curve data was 
Figure 1: Partial least squares discrimination analysis (PLS-DA) graph used to distinguish the metabolomics profile of 
the two groups GR (n = 15) and PR (n = 19). Each point corresponds to the metabolomics profile of a patient.
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obtained by plotting the sensitivity and specificity values for 
each concentration of biomarkers and the threshold value 
for each metabolite was determined by searching for those 
that yielded both high sensitivity and specificity. The serum 
levels of the selected metabolic biomarkers Spd and Trp can 
be influenced by confounding effects such as age, BMI, and 
tumour stage. For this reason, the effect of these covariates 
on the sensitivity and specificity of ROC model, based on 
Trp and Spd metabolites, was investigated. The results of 
this investigation clearly showed that age, BMI and tumour 
stage had no effect on the predictive diagnostic power of 
Spd and Trp, indicating that these two metabolic biomarkers 
can be considered as independent factors for the response to 
neoadjuvant treatment (Figure S1 supplementary data). In 
Figure 7, the ROC curves for Spd, Trp, and Trp/Spd ratio 
with the associated area under curve (AUC) are reported. 
Considering Spd and Trp as single biomarkers, the AUC 
[95% confidence interval] was 0.83 [0.67–0.95] and 0.87 
[0.72–0.98] respectively, whilst the AUC value increased 
to 0.93 [0.82–1.00] when the Trp/Spd ratio was used. 
Therefore, using a threshold value of 565 for the Trp/Spd 
ratio it was possible to distinguish patients achieving a 
pCR after neoadjuvant treatment with high sensitivity 0.90 
[0.79–1.00] and high specificity 0.87 [0.67–1.00].
DISCUSSION
In this pharmacometabolomics investigation, we 
applied a targeted metabolomics approach to assess the 
diagnostic potential of endogenous pre-treatment serum 
metabolites profile to predict the response to trastuzumab-
paclitaxel treatment in a neoadjuvant setting. Unlike 
previous clinical metabolomics investigations [26, 27] 
this study focused on a homogeneous population of BC 
patients. We have observed that patients with higher 
serum concentrations of Spd and lower concentrations of 
Trp would be more likely to benefit from trastuzumab–
paclitaxel neoadjuvant treatment. The Spd, spermine, and 
Put are essential ubiquitary cellular polyamines essentially 
constituted of organic polycations having variable 
hydrocarbon chains and two or more primary amino 
groups [28]. These chemical features are responsible 
for their essential role in DNA and RNA metabolism, 
maintenance of chromatin structure, regulation of specific 
gene expression, ion channel modulation and membrane 
stability. The key step in the production of polyamines is 
regulated by Orn decarboxylase (ODC), which is required 
for the production of Put. Subsequently, propylamino-
transferase catalyzes the transfer of Put of the aminopropyl 
Figure 2: Metabolites that produce the largest contribution in discriminating between GR and PR groups in the 
PLS-DA model, relative to the VIP score.
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group from decarboxylated S-adenosylmethionine to form 
Spd and spermine, respectively (Figure 5). This process 
is important because polyamines are essential for growth 
and differentiation of cells. In general, high concentrations 
of polyamines are found in rapidly growing cells, while 
low concentrations are present in quiescent cells [29, 30]. 
An increased production is observed in many cancer 
tissues including BC [31]. However, the function of such 
high concentrations of polyamines in tumour cells is 
not clear. In a study addressed to evaluate the variation 
of polyamines in the pre and post-surgery serum of BC 
patients, no significant difference was reported [32]. 
This suggests that the circulatory level of polyamines 
is more likely to represent an individual’s general 
physio-pathological condition. Thus, the difference in 
the Spd level between the GR and PR groups observed 
in this study could represent a host’s metabolic feature 
not representative of the tumour’s metabolic activity. 
In addition, the low level of serum Spd in the PR group 
appears not to be associated with differences in the level of 
Orn, Arg, Met and Put. Thus indicating that it may not be 
due to a shortage of the metabolite precursors. Moreover, 
the Orn/Spd and Put/Spd ratios, considered as surrogate 
parameters of Spd biosynthesis efficacy, were both lower 
in the GR group compared to PR patients. This suggests 
that a high synthetic rate of Spd could be a characteristic 
of patients that are more likely to achieve a pCR. 
However, a reduced catabolic clearance of Spd could also 
explain the higher concentration of Spd observed. Further 
investigation into the clearance of acetyl derivatives 
of polyamine [33] may give a more comprehensive 
explanation for the elevated Spd serum levels observed 
in the GR group. 
It is possible that a high level of circulating 
Spd could be translated into a high concentration of 
polyamines in the tumour microenvironment that may 
boost cell replication, thus improving paclitaxel activity. 
This drug promotes the assembly of microtubules 
from tubulin dimers and stabilises them by preventing 
depolymerisation. This stability may cause the inhibition 
of the normal dynamic reorganisation of the microtubule 
network, which is essential for vital interphase and 
Figure 3: Heatmap of the relative concentration of five metabolites with VIP > 1 in the serum of the GR and PR groups 
of patients according to the response to trastuzumab-paclitaxel treatment.
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mitotic cellular functions. Since Spd has been reported to 
improve tubulin assembly [34], a high concentration of 
this polyamine may also have a synergistic effect on the 
stabilization of microtubules, thus potentially increasing 
paclitaxel cytotoxicity.
The other relevant metabolic features that 
characterised the GR group of patients was the lower 
level of Trp. This metabolite is required for both protein 
synthesis and other important metabolic functions [35]. 
Low Trp serum levels may depend on a reduced dietary 
intake or an increase in its catabolism. Two major non-
protein metabolic routes use Trp as a precursor: (a) the 
methoxyindoles pathway, involved in the synthesis of Set 
and Melatonin; and (b), the Kyn pathway, responsible 
for the production of Kyn through Niacin synthesis. 
Low levels of Trp, due to an increase activity of the 
Kyn pathway, can suppress the immune system [36–38]. 
Furthermore, the induction of this pathway has been 
recently proposed as a potential mechanism activated 
by the tumour to escape immune surveillance [39;40]. 
Therefore, the involvement of Trp in the modulation of 
the immune system could be relevant for the immune-
mediated activity of trastuzumab. Trastuzumab confers 
cytostatic effects through direct interaction with HER-2 
receptors expressed by cancer cells suppressing the HER-2 
dependent signalling pathway [41]. However, other 
mechanisms of action involving immune cells have been 
proposed for trastuzumab: the antibody-dependent cellular 
cytotoxicity (ADCC), which involves especially Natural 
Killer cells, and the activation of HER-2-specific cytotoxic 
T-cells (CD8+) [14, 42]. Thus, the level of tryptophan and 
its catabolic product in the tumour microenvironment may 
contribute to modulate the immunocytoxic side activity 
induced by Trastuzumab. 
When the levels of Kyn and Set were compared 
between the two groups, the GR showed lower levels of 
Kyn, suggesting that the lower amount of Trp observed 
was not due to an increased catabolism. Both groups 
had the same Kyn catabolic activity as demonstrated by 
the lack of significant differences in the Trp/Kyn ratio. 
Conversely, an increase in Trp anabolism via the Set 
pathway could also be potentially relevant in the PR 
group as reported by the lower Trp/Set ratio observed. 
The low availability of Trp may be associated with a 
Figure 4: Significance analysis of microarray plot sheet output (SAM) under the four sets of criteria: cutup = 3.916, 
cutlow = 3.914; false=0.07; FDR = 0.032; which are indicated at the upper right corner. The red, green, and black dots 
represent upregulated, downregulated, and insignificant metabolites.
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Figure 5: Polyamine biosyntethic pathway and the mean concentration [µM] of metabolites among the GR and PR 
groups of patients. A p value of *p < 0.05 and **p < 0.001 was considered statistically significant. AdoMet: S-Adenosyl-Methionine, 
DC-AdoMet: Decarboxylated S-Adenosyl-Methionine, AdoT: S-AdenosylTransferase, AdoMDC: S-Adenosyl-Methionine Decarboxylase, 
ODC: Ornitine Decarboxylase, PAT(I and II): PropylAminoTransferase-1 and 2, ATP: AdenosylTriphosphate. SMA: S-MethylAdenosyl. 
PLP: Pyridoxal-5′-Phosphate, (*) Spermine and Spermidine can be inter converted to Putrescine in two steps catalized by the (1) Spermine/
Spermidine-N-1-AcetylTransferase (SSAT); (2) Polyamine Oxidase (PO).
Figure 6: Tryptophan catabolic pathway and the mean concentration [µM] of metabolites among the GR and PR 
groups of patients. A p value of *p < 0.05 and **p < 0.001 was considered statistically significant. TH: Tryptophan Hydroxylase, 
AADC: Aromatic Amino Acid Decarboxylase, NAT: N-Acetyl Transferase, HMT: 5-Hydroxylindole-O-MethylTransferase, Indoleamine-2, 
3 dioxygenase, F: Formamidase.
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reduced Kyn biosynthesis, which acts as inhibitor of the 
immune response and thus may have a positive impact on 
the trastuzumab activity, contributing to the induction of a 
pCR in the GR group. 
Finally and more importantly, the serum pre-
treatment levels of both Spd and Trp can be used as 
predictive markers to distinguish patients who are more 
likely to achieve pCR after trastuzumab-paclitaxel 
neoadjuvant treatment. In fact, when the two metabolites 
were combined in the Trp/Spd ratio, the inter-patient 
variation was reduced and the diagnostic power reached a 
high sensitivity of 90% with a specificity of 87% (Figure 7). 
In conclusion, this exploratory study demonstrated 
the importance of highlighting endogenous metabolic 
pathways that could favour the efficacy of neoadjuvant 
trastuzumab-paclitaxel treatment in HER-2 positive BC 
patients. The pharmacometabolomics approach adopted 
identified two major metabolic biomarkers represented by, 
Spd and Trp, that could potentially have a pivotal role in 
determining the efficacy of a trastuzumab-paclitaxel drug 
combination. Such an individual metabolic signature could 
be translated into a non-invasive diagnostic tool to select 
Figure 7: Receiving operating and scatter plots curve for (a) Spd, (b) Trp and (c) Trp/Spd ratio. Area under curve plots 
(95% confidence interval in brackets).
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patients more likely to benefit from neoadjuvant treatment. 
Although these preliminary results are very encouraging, 
they are based upon a relatively small sample size and 
additional studies with an increased number of patients 
will be needed to confirm and clinically validate  these 
exciting observations. 
MATERIALS AND METHODS
Patients’ population
Thirty-four patients were enrolled in this 
investigation. All patients had histologically confirmed 
locally advanced HER-2 positive BC (UICC stage II–III, 
non-inflammatory); patients were not previously 
treated with chemotherapy or hormonal therapy, an 
age ≤ 70 years, an Eastern Cooperative Oncology 
Group performance status ≤ 1, adequate hepatic, renal 
and bone marrow function. No CNS metastases, prior 
myocardial infarction or uncontrolled arrhythmia, angina 
pectoris, psychiatric syndromes or other serious medical 
conditions were present. Furthermore, no other concurrent 
malignancy, apart from non-melanoma skin cancer, or 
in situ cervix carcinoma was allowed.
Baseline evaluation included a physical 
examination, diagnostic breast imaging, abdominal 
ultrasound and bone scintigraphy. This study was carried 
out according to the ethical principles of the Declaration of 
Helsinki and approved by the Internal Institutional ethics 
committee. All patients enrolled in the investigation gave 
written informed consent.
Clinical samples
After a period of overnight fasting, each patient 
provided a 5 ml blood sample on the first day of 
admission, prior to receiving the neoadjuvant therapy. 
The blood was drawn in the morning between 8 and 10 
a.m. to avoid variation due to circadian rhythms. Blood 
was collected in BD Vacutainer® tubes coated with silica 
particles as a clot activator. The blood was inverted five 
times and allowed 30 minutes clotting time and was then 
centrifuged at 2000g for 10 min at 4°C. Serum was then 
aliquot and frozen at –80°C until required for targeted 
metabolomics analysis.
Study design
All patients enrolled in this study received 
trastuzumab: loading dose 4 mg/kg intravenously, then 
2 mg/kg weekly and concomitant weekly paclitaxel 
(80 mg/m2) for 6 cycles. After neoadjuvant completion, 
patients underwent primary surgery, which consisted in a 
mastectomy or a quadrantectomy conservative treatment 
as well as axillary node dissection. In accordance to 
the histological response, the patients were classified 
in two groups: Good and Poor responders. The good 
responders (GR group) were patients who benefited from 
the treatment by achieving pCR corresponding to the 
histological disappearance of invasive cancer cells on 
breast tissue after surgery. Whilst patients who, after the 
neoadjuvant treatment, continued to show the presence 
of cancer cells in breast tissue were classified as poor 
responders (PR group).
The research of pre-treatment biomarkers predictive 
of the histological response was performed by analysing 
the quantitative differences in the serum targeted 
metabolomics profile among GR and PR group in a case-
control study.
Serum targeted metabolomics investigations
A high-throughput liquid chromatography tandem 
mass spectrometry (LC-MS/MS) platform has been 
applied to evaluate the serum metabolomics profile using 
the AbsoluteIDQ p180 Kit (Biocrates Life Sciences 
Innsbruck, Austria). The analytical system consisted 
of a liquid chromatography ultimate 3000 (Thermo 
Fisher Scientific Milan Italy) coupled with a 4000 Qtrap 
(ABsciex Framingham, MA, USA) mass spectrometer. 
The analytical method allows the quantification of 188 
targeted metabolites covering the following compound 
classes: amino acids, biogenic amines and polyamines 
(n = 40), acylcarnitine (n = 40), di-acyl-phosphatidyl 
lipids (n = 92), sphingolipids (n = 15) and total exoses 
(n = 1). The complete list of the all metabolites investigated 
was reported in Table 2. Briefly, 10 mL of serum were 
loaded onto a inserted filter in a 96 well sandwich plate, 
which already contained appropriate internal standards 
structurally identical but labeled with stable isotopes 
such as deuterium, 13C, or 15N. The filters were dried 
in nitrogen stream, amino acids were derivatized with 
5% phenylisothiocyanate reagent (PTC), and filters were 
dried again. After extraction of metabolites with 500 mL 
of 5 mM ammonium acetate in methanol, the solution was 
centrifuged through the filter membrane and diluted with 
water and MS running solvent. Final extracts were than 
analyzed by LC-MS/MS for amino acids and bioactive 
amines PTC-derivatives using a Zorbax SB 100 × 2.1 mm 
column (Agilent, Santa Clara CA, USA), while direct flow 
injection analysis (FIA-MS/MS) was used for the analysis 
of acylcarnitine and phospolipides. The specific signals 
of metabolites utilized for quantitation were achieved by 
multiple reaction monitoring, neutral loss and precursor 
ion scans in positive and negative ion mode. The MS/MS 
signals were integrated, by using Analyst 1.6.1(ABsciex 
Framingham, MA, USA) and concentrations obtained 
using a calibration curve according to the AS-180 manual. 
All quantitative data were further processed for verification 
and validation by the MetIQ software by comparing the 
results of triplicate analysis of low, medium and high 
quality serum controls as an integral part of the analytical 
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kit. Within the analytical batch the coefficient of variation 
for the quality control metabolites concentration was less 
than 20%, while the uncertainty of the measurements was 
found in the range of 80–115% of their theoretical values. 
Samples were analyzed in a random sequence with serum 
controls in compliance with Want et al. 2010 guidelines 
[43]. The metabolites with serum concentration above the 
limit of detection in at least 50% of all measured samples 
were excluded by successive statistical analysis. Among 
the serum samples investigated, about 18% of analyzed 
metabolites showed serum concentrations below the lower 
limit of quantification criteria and were not considered for 
further data analysis. The final number of metabolites 
analyzed was 153 (82%). This set included 17 (42%) 
acylcarnitines, 14 (100%) lysophosphatidyl coline lipids, 
72 (95%) phosphatidylcolines, 15 (100%) sphingomyelin 
lipids and 35 (83%) amino acids plus bioactive amine 
derivatives. The mean ± SD serum concentration of the 
validated metabolites among the GR and PR groups 
of patients are reported together with the statistical 
significance in supplemental data in Table S1
Data processing and statistical analysis
Prior to statistical analysis, the concentration 
values of metabolites were set to a log scale and auto-
Table 2: List of metabolite determined using LC and FIA MS/MS platform
Metabolite N
Amino acids 21 Ala, Arg, Asn, Asp, Cit, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Orn, Phe, Pro, Ser, Thr, Trp, Tyr, Val
Amino acid metabolism, urea-cycle, activity of 
gluconeogenesis
and glycolysis, insulin sensitivity, neurotransmitter 
metabolism,
oxidative stress
Biogenic-amine 19
ADMA, AcOrn, carnosine (*), creatinine, histamine, kynurenine, 
Met-SO, Nitro-Tyr, OH-Pro, PEA, Putrescine, SDMA, 
sarcosine,serotonin,
spermidine, spermine, taurine, alpha-AAA,totalDMA
Neurological disorders, cell proliferation, cell cycle 
progression, DNA stability, 
oxidative stress
Carnitine 1 C0
Energy metabolism, fatty acid transport and 
mitochondrial
fatty acid oxidation, ketosis, oxidative stress, 
mitochondrial
membrane damage
Acylcarnitines 26
C2, C3, C3:1, C4, C4:1, C5, C5:1, C6 (or C4:1-DC), C6:1, C8, 
C8:1, C9, C10, C10:1, C10:2, C12, C12:1,C14, C14:1, C14:2, 
C16, C16:1, C16:2, C18, C18:1,C18:2
“
Hydroxy- and 
dicarboxyacylcarnitines 13
C3-OH, C4-OH (or C3-DC), C5-DC (or C6-OH), C5-OH(or 
C3-DC-M), C5:1-DC, C5-M-DC, C7-DC, C12-DC, C14:1-OH, 
C14:2-OH, C16:1-OH, C16:2-OH, C16-OH,C18:1-OH
“
Sum of hexoses 1 H1 Carbohydrate metabolism
Sphingomyelins 10 SM C16:0, SM C16:1, SM C18:0, SM C18:1, SMC20:2, SM C22:3, SM C24:0, SMC24:1, SM C26:0,SM C26:1
Signalling cascades, membrane damage 
(eg,neurodegeneratio)n
Hydroxysphingomyelins 5 SM (OH) C14:1, SM (OH) C16:1, SM (OH) C22:1, SM(OH) C22:2, SM (OH) C24:1 “
Diacyl-
phosphatidylcholines 38
PC aa C24:0/C26:0/C28:1/C30:0/C30:2/C32:0/C32:1/C32:2/
C32:3/C34:1/C34:2/C34:3/C34:4/C36:0/C36:1/C36:2/C36:3/
C36:4/C36:5/C36:6/C38:0C38:1/C38:3/C38:4/C38:5/C38:6/
C40:1/C40:2C40:3/C40:4/C40:5/C40:6/C42:0/C42:1/C42:2/
C42:4/C42:5/C42:6
Degradation of phospholipids, membrane damage, 
signalling
cascades, fatty acid profile
Acyl-alkyl-
phosphatidylcholines 39
PC ae 
C30:0/C30:1/C30:2/C32:1/C32:2/C34:0/C34:1/C34:2/C34:3/
C36:0/C36:1/C36:2/C36:3/C36:4/C36:5/C38:0/C38:1/C38:2/
C38:3/C38:4/C38:5/C38:6/C40:0/C40:1/C40:2/C40:3/C40:4/
C40:5/C40:6/C42:0/C42:1/C42:2/C42:3/C42:4/C42:5/C44:3/
C44:4/C44:5/C44:6
“
Lyso-
phosphatidylcholines 15
lysoPC aa C6:0/C14:0/C16:0/C16:1/C17:0/C18:0/C18:1/C18:2/
C20:3/C20:4/C24:0/C26:0/C26:1/C28:0/C28:1
Degradation of phospholipids (phospholipase 
activity), membrane damage, signaling cascades, 
fatty acid profiles
aa, acyl-acyl; ae, acyl-alkyl; a, lyso; Cx:y, where x is the number of carbons in the fatty acid side chain; y is the number 
of double bonds in the fatty acid side chain; DC, decarboxyl; M,methyl; OH, hydroxyl; PC, phophatidylcholine; SM, 
sphingomyelin. (*) Underlined the metabolites that did not pass the analytical quality control process. 
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scaled (mean-centred and divided by the standard 
deviation of each variable). A supervisor multivariate 
partial least squares discrimination analysis (PLS-DA) 
was then applied to identify the relevant metabolites 
that contribute the most significantly in differentiating 
between the two groups of patients. The PLS model was 
refined by incorporating only the metabolite variable that 
was identified as being significantly different among the 
two groups of patients (p < 0.05). A variable importance 
in projection (VIP) score was also applied to rank the 
patient’s metabolites that best distinguished between 
the GR vs PR group.  The PSA-DA model was further 
cross-validated by comparison of the resulting goodness 
of fit (R2), predictive ability (Q2) values, and by internal 
validation using 1000 permutation tests. Q2 represents 
the most recognized diagnostic statistical parameter 
to validate the PLS-DA model in metabolomics. It is 
calculated as 1-PRESS/TSS where PRESS is the sum of 
squared differences between the predicted and real value, 
while the TSS is the total sum of the square. Significant 
predictive model is considered for Q2 value greater than 
0.4. R2 indicates the total variation in the data matrix that 
is explained by the model. It is calculated as 1- RSS/TSS 
where the RSS is the fitted residual sum of the square 
of the data. An invalid or irrelevant model may be still 
capable of producing a large Q2 value, because consistent 
cross-validation requires a systematic deletion of large 
portions of the dataset during training. Thus, further 
validation of the model was performed by random 1000 
permutation of class labels, which requires no deletion 
of data, with internal leave-n-out cross-validation. 
Significance of permutation test was expressed as pseudo 
p calculated as number of failed prediction / numbers of 
permutation performed.
The significant features were further selected by 
taking into account the problem of false discovery rate 
(FDR) occurring for multiple analyses [44], through the 
application of the significance analysis of microarray 
(SAM) approach. An un-paired t-test was used as a 
univariate analysis to check the differences in the serum 
concentrations of single metabolites between the GR 
and the PR groups. For all the above univariate tests 
q values were calculated to control for multiple testing 
false discovery rate.
Receiver operating characteristic (ROC) curves 
analysis was used to determine the diagnostic power of 
the more significant metabolomics biomarkers. In a ROC 
curve, the true positive rate (sensitivity) was plotted 
against the false positive rate (1-specificity) for different 
cut-off points of a given parameter. The ROC curve was 
validated by Internal cross validation and permutation 
testing. The optimal cut-off was assessed by jointly 
maximizing sensitivity and specificity. Sensitivity and 
specificity, computed at the optimal cut-off, were then 
used for further investigation. All above data processing 
and the statistical analysis that included ROC analysis was 
performed using the Metabolanalyst web portals [45, 46]. 
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